Wealthspire Advisors (Maryland)’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Wealthspire Advisors (Maryland)’s Portfolio EGRX Stock Details EGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-40	Closed	-$2K	–	2155
2019 Q1	$2K	Buy	40 +6	+18%	+$267	﹤0.01%	2227
2018 Q4	$1K	Buy	+34	New	+$1.75K	﹤0.01%	2357
2018 Q1	–	Sell	-16	Closed	-$1K	–	2670
2017 Q4	$1K	Buy	16 +14	+700%	+$779	﹤0.01%	2364
2017 Q3	$0	Buy	+2	New	+$121	﹤0.01%	2498
2016 Q1	–	Sell	-15	Closed	-$1K	–	1864
2015 Q4	$1K	Buy	+15	New	+$1.18K	﹤0.01%	1667

Other funds holding EGRX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

HEC

Hudson Executive Capital New York $151M AUM 60.14% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Wealthspire Advisors (Maryland)'s EGRX Position: Q2 2019 in Review

Wealthspire Advisors (Maryland) sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q2 2019, closing a stake of 40 shares — an estimated $2K sold.

Wealthspire Advisors (Maryland) first reported a position in EGRX in Q4 2015 and held it in 5 quarters. The position peaked at $2K in Q1 2019. 180 funds tracked by Wall St. Rank hold EGRX as of Q2 2019.

Wealthspire Advisors (Maryland) reported no remaining Eagle Pharmaceuticals, Inc. position as of Q2 2019 after selling out during the quarter.
Wealthspire Advisors (Maryland) sold 40 Eagle Pharmaceuticals, Inc. shares in Q2 2019, an estimated $2K.
Wealthspire Advisors (Maryland) first reported a position in Eagle Pharmaceuticals, Inc. in Q4 2015 and held it in 5 quarters.
Wealthspire Advisors (Maryland)'s Eagle Pharmaceuticals, Inc. position peaked at $2K in Q1 2019.
180 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q2 2019.

Based on Wealthspire Advisors (Maryland)'s 13F filing for Q2 2019, filed 12 Aug 2019.